Evidence map›Paper›PMID 39083135›Full record

ArticleEJNMMI radiopharmacy and chemistry2024

The development of

Xiaobei Zheng, Shuai Xue, Zhongqi Zhao, Shuxin Jin, Shuhua He, Lina Jia, Zheng Li, Christian Vanhove, Filip De Vos, Zijun Kuang and 4 more

Abstract read
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Development of AlPharmaceutics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xiaobei Zheng *Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Shuai Xue *Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Zhongqi ZhaoShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Shuxin JinShanghai Vista Pharmaceutical Technology Co. Ltd, Shanghai, 201800, China.
Shuhua HeShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Lina JiaShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Zheng LiShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Christian VanhoveInstitute of Biomedical Engineering and Technology, Faculty of Engineering and Architecture, Ghent University, Ghent, 9000, Belgium.
Filip De VosDepartment of Radiopharmacy, Faculty of Pharmacy, Ghent University, Ghent, 9000, Belgium.
Zijun KuangShanghai Vista Pharmaceutical Technology Co. Ltd, Shanghai, 201800, China.
Tiantian WangShanghai Vista Pharmaceutical Technology Co. Ltd, Shanghai, 201800, China.
Sara NeytInstitute of Biomedical Engineering and Technology, Faculty of Engineering and Architecture, Ghent University, Ghent, 9000, Belgium. Sara.Neyt@UGent.be.
Lan ZhangShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China. zhanglan@sinap.ac.cn.
Xiao LiShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China. lixiao@sinap.ac.cn.

Funding

Clinical research program of Health Industry of Shanghai Municipal Commission of Health 202150002National Natural Science Foundation of China 82272042Pudong Hospital, Fudan University, College Level Project YJYJRC202108/YJYJRC202101/Zdzk2020-14The Pudong New Area Clinical Characteristic Discipline Project No. PWYts2021-01
6 · The paper itself

Abstract

backgroundCurrently, the synthesis pathway of metal nuclide-labeled radiopharmaceuticals is mainly divided into two steps: first, connecting the chelator with the target molecule, and second, labeling the metal nuclide to the chelator. However, the second step of the reaction to label the metal nuclide requires high temperature (90-100 °C), which tends to denature and inactivate the target molecule, leading to loss of biological activities, especially the targeting ability. A feasible solution may be the click chemistry labeling method, which consists of reacting a metal nuclide with a chelating agent to generate an intermediate and then synthesizing a radiopharmaceutical agent via the click chemistry intermediate and the target molecule-alkyne compound. In this study, through the click chemistry of

resultsA novel

conclusionThis study demonstrated the potential of click chemistry to unify the synthesis of metal radiopharmaceuticals, and

Indexed as

177Lu-DOTA-CC-PSMAAlkyneAzidoClick chemistryProstate cancerPSMA

Identifiers

PMID39083135
PMCPMC11291776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.